Pacira’s Exparel “Hit Where It Needed to Most” Pacira Pharmaceuticals Inc (NASDAQ:PCRX) shares were falling 12% yesterday after the drug maker’s pain medicine …
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) announced the publication of its Phase 4 PILLAR study of EXPAREL (bupivacaine liposome injectable suspension) in total knee arthroplasty (TKA). The …
Neuralstem Shares Collapse on Clinical Setback Shares of Neuralstem, Inc. (NASDAQ:CUR) were hit hard Tuesday after news that its MDD drug failed a …
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) started 2017 strong, pre-announcing a fourth-quarter of 2017 beat coupled with full-year results that outclassed consensus expectations. The biotech …
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) announced preliminary unaudited total revenues and EXPAREL (bupivacaine liposome injectable suspension) net product sales for the fourth quarter and …
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) announced a joint endeavor with GeneAlign, a therapeutic management and solutions company working to revolutionize personalized medicine through a …
Investors who listened to Irina Rivkind Koffler over the past year have made 17 percent on their Koffler bets, according to TipRanks. The analyst, …
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results …
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) announced the appointment of two key individuals who will assume leadership roles within the company’s commercial organization. Thomas Slubyhas been …
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) announced new data regarding the benefit of EXPAREL®(bupivacaine liposome injectable suspension) for patients undergoing third molar (wisdom teeth) extraction, marking …
